The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Continuous Bio-Manufacturing Skid Market During The Forecast Period?
The continuous bio-manufacturing skid market has seen rapid expansion in recent years. It is forecast to increase from $1.99 billion in 2025 to $2.26 billion in 2026, at a compound annual growth rate (CAGR) of 13.6%. The historical growth of this market can be attributed to several factors: an increase in biologics production volumes, an early transition from batch to continuous processing, the growing adoption of modular manufacturing concepts, the expansion of vaccine and enzyme production facilities, and the increasing demand for flexible manufacturing setups.
The continuous bio-manufacturing skid market is projected to experience substantial growth in the coming years. Its value is anticipated to reach $3.73 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This expansion during the forecast period is driven by factors such as the increasing deployment of fully continuous biologics production, rising investments in advanced bioprocess automation, a growing demand for rapid scale-up capabilities, the expansion of cell and gene therapy manufacturing, and an increasing emphasis on cost-efficient biologics production. Key developments throughout this period are expected to involve the increasing adoption of continuous and integrated bioprocessing skids, a rising demand for modular and plug-and-play manufacturing systems, the growing use of real-time process monitoring and control, the expansion of single-use continuous biomanufacturing platforms, and an enhanced focus on process efficiency and throughput.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28999&type=smp
Which Core Factors Are Supporting The Expansion Of The Continuous Bio-Manufacturing Skid Market?
The continuous bio-manufacturing skid market is expected to grow, propelled by the escalating demand for biopharmaceuticals. Biopharmaceuticals are medical products made from biological sources, including proteins, nucleic acids, or living cells, used to treat, prevent, or diagnose diseases. This increasing need for biopharmaceuticals is primarily driven by the rising incidence of chronic and genetic diseases, which necessitate advanced biologic therapies for effective treatment and management. Continuous bio-manufacturing skids improve biopharmaceutical production by facilitating streamlined, automated, and scalable processes, thereby enhancing the efficiency, consistency, and speed in developing complex therapies. For example, according to Cardinal Health Inc., a US-based healthcare company, in January 2023, the U.S. had 40 FDA-approved biosimilar products by 2023, with 25 available on the market. This is an increase from January 2022, when there were 33 FDA-approved biosimilars, of which 21 were commercially available. Consequently, the increasing demand for biopharmaceuticals is driving the expansion of the continuous bio-manufacturing skid market.
How Are Different Segment Groups Identified Within The Continuous Bio-Manufacturing Skid Market?
The continuous bio-manufacturing skid market covered in this report is segmented –
1) By Product Type: Single-Use Skids, Multi-Use Skids, Modular Skids
2) By Process: Upstream, Downstream, Integrated
3) By Application: Biopharmaceutical Production, Vaccine Manufacturing, Enzyme Production, Cell And Gene Therapy, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Institutes, Other End-Users
Subsegments:
1) By Single-Use Skids: Perfusion Bioreactor Skid, Tangential Flow Filtration Skid, Chromatography Skid, Buffer Preparation Skid
2) By Multi-Use Skids: Fed-Batch Bioreactor Skid, Downstream Purification Skid, Ultrafiltration Skid, Viral Inactivation Skid
3) By Modular Skid: Plug And Play Bioreactor Skid, Integrated Downstream Skid, Automated Sampling Skid, Real-Time Monitoring Skid
Which Trends Are Guiding The Development Of The Continuous Bio-Manufacturing Skid Market?
Leading companies in the continuous bio-manufacturing skid market are concentrating on developing innovative solutions, such as next-generation biologics manufacturing platforms, to improve efficiency, scalability, and product quality. These advanced systems facilitate fully connected, continuous production of biologics with real-time monitoring, greater efficiency, and consistent product quality. For example, in October 2024, Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, unveiled EnzeneX 2.0 at CPHI Milan 2024, representing the next evolution of its fully connected continuous manufacturing (FCCM) technology for biologics. This patented platform enables uninterrupted processing from perfusion to final drug substance. By utilizing high-titer clones and optimized cell media, it boosts productivity, increases target protein concentrations, and minimizes batch-to-batch variability. The system also integrates process analytical technology (PAT) for real-time monitoring and control, ensuring consistent quality and operational efficiency, while providing up to a 50% reduction in production costs per gram. These platforms deliver scalable, cost-effective biologics manufacturing adaptable to various modalities and media formulations.
Who Are The Companies Shaping The Continuous Bio-Manufacturing Skid Market Landscape?
Major companies operating in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, CPi Biotech Inc.
Access The Complete Continuous Bio-Manufacturing Skid Market Report:
Which Regional Market Leads The Continuous Bio-Manufacturing Skid Market?
North America was the largest region in the continuous bio-manufacturing skid market in 2025. The regions covered in the continuous bio-manufacturing skid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Continuous Bio-Manufacturing Skid Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28999&type=smp
Browse Through More Reports Similar to the Global Continuous Bio-Manufacturing Skid Market 2026, By The Business Research Company
Digital Biomanufacturing Market Report 2026
https://www.thebusinessresearchcompany.com/report/digital-biomanufacturing-global-market-report
Biopharmaceuticals Contract Manufacturing Market Report 2026
Bioengineering Technology Market Report 2026
https://www.thebusinessresearchcompany.com/report/bioengineering-technology-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model